Myo-inositol supplemention effectively reduces the need for insulin therapy and improves insulin resistance in gestational diabetes. However, it does not affect birth weight, cesarean deliveries, and NICU admissions.
A study conducted by Huan Chen and colleagues substantiated the effectiveness of myo-inositol supplements for gestational diabetes management. This meta-analysis investigated myo-inositol's impact on metabolic status in affected women. Investigators conducted a systematic search of databases, including Cochrane Library, EBSCO, Web of Science, Embase, and PubMed for randomized controlled trials (RCTs) assessing myo-inositol's effects on gestational diabetes outcomes in women.
Gestational diabetes was identified if any glucose concentration threshold was surpassed, with the cut-off values being 92, 180, and 153 mg/dl for fasting, 1 hour, and 2 hours, respectively, following a 75-gram, 2-hour oral glucose tolerance test. For continuous outcomes, researchers calculated the standard mean difference (SMD) along with 95% confidence intervals (CI). For dichotomous outcomes, the odds ratio (OR) along with 95% CIs were estimated. The analysis included 4 RCTs with 317 patients.
Compared to standard therapy for gestational diabetes in pregnant women, myo-inositol supplementation markedly diminished the necessity for insulin therapy (odds ratio [OR] = 0.24) and also improved homeostasis model assessment of insulin resistance (HOMA-IR; SMD = -1.18). However, it exhibited no vital effect on birth weight (SMD = -0.11), cesarean section rates (OR = 0.82), or the need for neonatal intensive care unit (NICU) admission (OR = 0.88). Thus, supplementing with myo-inositol is beneficial for reducing the reliance on insulin therapy and improving insulin resistance in gestational diabetes.
The Journal of Maternal-Fetal & Neonatal Medicine
Influence of myo-inositol on metabolic status for gestational diabetes: a meta-analysis of randomized controlled trials
Huan Chen et. al.
Comments (0)